Evaluation of serum IgM and IgG antibodies in COVID‐19 patients by enzyme linked immunosorbent assay

Chang Zhou,Ge Bu,Yong Sun,Cuiping Ren,Mingsheng Qu,Yufeng Gao,Yulin Zhu,Linding Wang,Liang Sun,Yan Liu
DOI: https://doi.org/10.1002/jmv.26741
IF: 20.693
2021-03-01
Journal of Medical Virology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>SARS‐CoV‐2 is sweeping the world since the end of 2019. The titer change of antibodies against SARS‐CoV‐2 needs to be further clarified, the clinical and preventive value of antibodies still needs to be further investigated.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>An ELISA was established by coating with SARS‐CoV‐2 recombinant spike protein and used to detect serum IgM and IgG antibodies against SARS‐CoV‐2 in COVID‐19 patients to evaluate the pattern of changes of antibodies.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The specificity of the ELISA for detection SARS‐CoV‐2 IgM and IgG were 96% (144/150) and 100% (150/150), respectively. The sensitivity of ELISA was 100% (150/150) for IgM, and 99.3% (149/150) for IgG. SARS‐CoV‐2‐SP‐IgM and SP‐IgG antibodies could be detected on day 1 of hospitalization in 12.5% patients, and SP‐IgM began to decrease after reaching its peak at around 22‐28 days, and become negative at month 3 in 30% patients and negative at month 7 in 79% of these patients after onset; IgG reached its peak around day 22‐28 and kept at a high level within the longest observation period for 4 months, it dropped very sharply at 7 months. The positive rates of SP‐IgM and SP‐IgG were higher than those of RT‐qPCR on day 7 and 4.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>The established indirect ELISA has good specificity and sensitivity. IgM and IgG against SARS‐CoV‐2 appeared almost simultaneously in the early stage, and the level of IgG antibodies couldn't maintain a high plateau in the observation period of 7 months. Our data will help develop the diagnosis and vaccine of SARS‐CoV‐2.</p><p>This article is protected by copyright. All rights reserved.</p></section>
virology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to understand the changing patterns of IgM and IgG antibodies in the human body after infection with SARS - CoV - 2 and their clinical values. Specifically, researchers hope to detect the levels of IgM and IgG antibodies in the sera of COVID - 19 patients through enzyme - linked immunosorbent assay (ELISA) technology, in order to evaluate the changing trends of these antibodies at different stages of the disease and their significance for diagnosis and vaccine development. ### Research Background - **SARS - CoV - 2 Infection**: Since the end of 2019, SARS - CoV - 2 has spread rapidly around the world, causing serious public health problems. - **Antibody Changes**: After SARS - CoV - 2 infection, the changing patterns of antibodies (especially IgM and IgG) produced by the human body need to be further clarified, and the clinical and preventive values of these antibodies also need further research. - **Limitations of Existing Diagnostic Methods**: Currently, it mainly depends on RT - qPCR technology to detect viral RNA, but this method may produce false - negative results in some cases, so other diagnostic means are needed as supplements. ### Research Objectives - **Establish ELISA Method**: By using the SARS - CoV - 2 recombinant spike protein (S protein) as an antigen, establish an indirect ELISA method for detecting IgM and IgG antibodies in the sera of COVID - 19 patients. - **Evaluate Antibody Changes**: Analyze the changing trends of IgM and IgG antibodies at different stages of the disease, especially the dynamic changes from the early stage of infection to 7 months later. - **Verify the Specificity and Sensitivity of the Method**: Evaluate the specificity and sensitivity of the established ELISA method in detecting SARS - CoV - 2 - specific IgM and IgG antibodies. - **Clinical Application Value**: Explore the potential application values of IgM and IgG antibodies in early diagnosis, disease progression monitoring, and vaccine development. ### Main Findings - **Specificity and Sensitivity**: The specificity of the established ELISA method for SARS - CoV - 2 IgM and IgG antibodies is 96% and 100% respectively, and the sensitivity is 100% and 99.3% respectively. - **Antibody Changing Trends**: - **IgM Antibody**: It can be detected on the first day of hospitalization, reaches its peak at about 22 - 28 days, and then gradually decreases. 30% of patients turn negative after 3 months, and 79% of patients turn negative after 7 months. - **IgG Antibody**: It reaches its peak at about 22 - 28 days and remains at a relatively high level within 4 months, but decreases significantly at 7 months. - **Comparison with RT - qPCR**: In the early stage of the disease (days 1 - 3), the positive rate of RT - qPCR is higher than that of IgM and IgG antibody detection; but starting from the 7th day, the positive rates of IgM and IgG antibodies gradually exceed that of RT - qPCR. ### Conclusions - **Effectiveness of ELISA Method**: The established indirect ELISA method has good specificity and sensitivity and can effectively detect SARS - CoV - 2 - specific IgM and IgG antibodies. - **Clinical Significance of Antibody Changes**: IgM and IgG antibodies appear almost simultaneously in the early stage of the disease, and the high - level maintenance time of IgG antibody within the observation period is limited. These data are helpful for improving the diagnosis methods of SARS - CoV - 2 and vaccine research and development. ### Future Directions - **Long - term Follow - up Research**: Continue to track the antibody changes of patients, especially the changing trends in a longer period. - **Immune Response Mechanism**: Further study the mechanism of IgM and IgG antibodies in clearing the virus and protecting patients from reinfection. - **Vaccine Development**: Explore the potential of S protein as a vaccine component, and look for immunogens and adjuvants that can cause stronger immune responses. Through these studies, the immune response after SARS - CoV - 2 infection can be better understood, providing a scientific basis for the diagnosis, treatment, and prevention of the disease.